Switching from branded alendronate or risedronate to generic alendronate: Effect on persistence with bisphosphonate therapy in Germany

被引：0
|
作者：
Ziller, V. [1 ]
Schuessel, K.
Czeche, S.
Franzmann, A.
Kloeckner, D.
Quinzler, R.
Schulz, M. [2 ]
Moehrke, W. [3 ]
Hadji, P. [1 ]
机构：
[1] Univ Hosp Giessen & Marburg, Dept Gynecol, Marburg, Germany
[2] DAPI Verein Deutsch Arzneiprufungsinst eV, Eschborn, Germany
[3] Procter & Gamble Pharmaceut, Schwalbach A Ts, Germany
来源：
BONE | 2009年 / 44卷 / 02期
关键词：
D O I：
10.1016/j.bone.2009.03.423
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S449 / S450
页数：2
相关论文
共 50 条
  • [1] SWITCHING FROM BRANDED ALENDRONATE OR RISEDRONATE TO GENERIC ALENDRONATE: EFFECT ON PERSISTENCE WITH BISPHOSPHONATE THERAPY IN GERMANY
    Ziller, V.
    Schuessel, K.
    Czeche, S.
    Franzmann, A.
    Kloeckner, D.
    Quinzler, R.
    Schulz, M.
    Moehrke, W.
    Hadji, P.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 112 - 112
  • [2] The effect of switching patients from risedronate to alendronate on the risk of upper gastrointestinal (GI) adverse events after the introduction of generic alendronate products in the UK
    Ralston, S. H.
    Kuo, T. D.
    Wick-Urban, B.
    Steinbuch, M.
    BONE, 2009, 44 (02) : S446 - S446
  • [3] The risk of upper gastrointestinal (GI) adverse events of patients switching from risedronate to alendronate after the introduction of generic alendronate products in the UK
    Ralston, S. H.
    Kou, T. D.
    Wick-Urban, B. C.
    Steinbuch, M.
    BONE, 2009, 44 : S114 - S115
  • [4] Persistence and adherence to alendronate and risedronate among chronic glucocorticoid users
    Curtis, JR
    Westfall, AO
    Allison, JJ
    Freeman, A
    Kiefe, CI
    Staag, KG
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S734 - S735
  • [5] Persistence of drug treatment with alendronate and risedronate in primary care patients
    Moehrke, W
    Lyssy, A
    Wick, B
    Gerd, M
    VALUE IN HEALTH, 2005, 8 (06) : A138 - A138
  • [6] Bisphosphonate therapy and hip fractures within the risedronate and alendronate (REAL) cohort study: A comparison to patients with minimal bisphosphonate exposure
    Delmas, P. D.
    Silverman, S. L.
    Watts, N. B.
    Lange, J. L.
    Lindsay, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S328 - S328
  • [7] RISK OF UPPER GASTROINTESTINAL (GI) TRACT EVENTS IN RISEDRONATE AND/OR ALENDRONATE USERS IN THE ERA OF MARKETED GENERIC ALENDRONATE PRODUCTS
    Ralston, S. H.
    Kou, T. D.
    Wick-Urban, B. C.
    Steinbuch, M.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 (01) : 184 - 184
  • [8] Bisphosphonate therapy and hip fractures within the risedronate and alendronate (REAL) cohort study: Subgroup with prior fracture
    Delmas, P. D.
    Silverman, S. L.
    Watts, N. B.
    Lange, J. L.
    Lindsay, R.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S221 - S221
  • [9] Detection, by XRay Diffraction, of new bisphosphonate polymorphs of alendronate and risedronate treated hydroxyapatite
    Fernandez, Maria Emilia
    Fabregas, Ismael
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2011, 67 : C564 - C564
  • [10] Response to therapy - Identifying nonresponders to risedronate compared with alendronate
    Kagan, Risa
    Saag, Kenneth
    Bonnick, Sydney
    Rosenberg, Elizabeth
    Chen, Erluo
    de Papp, Anne E.
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 82S - 82S
12345